Why the study?
Does spironolactone reduce albuminuria and blood pressure in type 2 diabetic patients with nephropathy?
Does spironolactone reduce albuminuria and blood pressure in type 2 diabetic patients with nephropathy?
Adding spironolactone to maximal ACEi/ARB therapy reduces albuminuria and blood pressure in patients with type 2 diabetes and nephropathy.
Answers are grounded in this paper and cite their sources.
Supports spironolactone addition to ACEi/ARB in diabetic nephropathy; extends RCT evidence for additive renoprotection.
Our study suggests that spironolactone safely adds to the reno- and cardiovascular protective benefits of treatment with maximally recommended doses of ACE inhibitor and ARB by reducing albuminuria and blood pressure in type 2 diabetic patients with nephropathy.
No takes yet. Share an insight, caveat, or question.
Rossing et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: